EA201200919A1 - Конъюгат с обнаруживающим мишень лигандом и его применение - Google Patents

Конъюгат с обнаруживающим мишень лигандом и его применение

Info

Publication number
EA201200919A1
EA201200919A1 EA201200919A EA201200919A EA201200919A1 EA 201200919 A1 EA201200919 A1 EA 201200919A1 EA 201200919 A EA201200919 A EA 201200919A EA 201200919 A EA201200919 A EA 201200919A EA 201200919 A1 EA201200919 A1 EA 201200919A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugat
application
target ligand
detecting target
detecting
Prior art date
Application number
EA201200919A
Other languages
English (en)
Other versions
EA023893B1 (ru
Inventor
Карстен Рудольф
Иоганнес-Петер Гайгер
Original Assignee
Этрис Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Этрис Гмбх filed Critical Этрис Гмбх
Publication of EA201200919A1 publication Critical patent/EA201200919A1/ru
Publication of EA023893B1 publication Critical patent/EA023893B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric

Abstract

Описывается конъюгат из агентного комплекса и по меньшей мере одного обнаруживающего мишень лиганда, причем агентный комплекс включает покрытый оболочечным материалом агент и причем обнаруживающий мишень лиганд представляет собой аналог простациклина, а также его применение.
EA201200919A 2009-12-21 2010-12-21 Конъюгат с обнаруживающим мишень лигандом и его применение EA023893B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015812A EP2338520A1 (de) 2009-12-21 2009-12-21 Konjugat mit Zielfindungsligand und dessen Verwendung
PCT/EP2010/007846 WO2011076391A1 (de) 2009-12-21 2010-12-21 Konjugat mit zielfindungsligand und dessen verwendung

Publications (2)

Publication Number Publication Date
EA201200919A1 true EA201200919A1 (ru) 2013-02-28
EA023893B1 EA023893B1 (ru) 2016-07-29

Family

ID=41727502

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200919A EA023893B1 (ru) 2009-12-21 2010-12-21 Конъюгат с обнаруживающим мишень лигандом и его применение

Country Status (13)

Country Link
US (4) US8871230B2 (ru)
EP (3) EP2338520A1 (ru)
JP (1) JP5748768B2 (ru)
KR (1) KR101769638B1 (ru)
CN (1) CN102770161B (ru)
AU (1) AU2010335528B2 (ru)
BR (1) BR112012015147B1 (ru)
CA (1) CA2784705C (ru)
DK (1) DK2515945T3 (ru)
EA (1) EA023893B1 (ru)
ES (1) ES2687442T3 (ru)
WO (1) WO2011076391A1 (ru)
ZA (1) ZA201204480B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871230B2 (en) 2009-12-21 2014-10-28 Ethris Gmbh Conjugate with target-finding ligand and use thereof

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
PT2506857T (pt) 2009-12-01 2018-05-14 Translate Bio Inc Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
ES2737960T3 (es) 2010-10-01 2020-01-17 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos
RS55624B1 (sr) 2011-02-07 2017-06-30 Scipharm Sàrl Nova kompozicija za lečenje cistične fibroze
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
JP6522337B2 (ja) 2011-05-11 2019-05-29 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
TR201910686T4 (tr) 2011-06-08 2019-08-21 Translate Bio Inc Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler.
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
ES2826203T3 (es) 2012-06-08 2021-05-17 Ethris Gmbh Suministro pulmonar de ARN mensajero
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
CA2891673A1 (en) * 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
PL2968586T3 (pl) 2013-03-14 2019-01-31 Translate Bio, Inc. Kompozycje mrna cftr i związne z nimi sposoby i zastosowania
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
NZ718817A (en) 2013-10-22 2020-07-31 Massachusetts Inst Technology Lipid formulations for delivery of messenger rna
AU2015266764B2 (en) 2014-05-30 2019-11-07 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
CN106795142B (zh) 2014-06-24 2022-11-04 川斯勒佰尔公司 用于递送核酸的立体化学富集组合物
US10849920B2 (en) 2015-10-05 2020-12-01 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
CN117503905A (zh) 2015-10-07 2024-02-06 阿佩利斯制药有限公司 给药方案
IL310250A (en) 2016-05-05 2024-03-01 Liquidia Tech Inc Terfostinil in dry powder form for the treatment of pulmonary hypertension
WO2018127382A1 (en) 2017-01-03 2018-07-12 Ethris Gmbh Ornithine transcarbamylase coding polyribonucleotides and formulations thereof
MA47603A (fr) 2017-02-27 2020-01-01 Translate Bio Inc Nouvel arnm cftr à codons optimisés
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
CA3059304A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
JP2021522228A (ja) 2018-04-25 2021-08-30 エスリス ゲーエムベーハーｅｔｈｒｉｓ ＧｍｂＨ Ｒｎａの送達用の脂質に基づく製剤
US20210316008A1 (en) 2018-08-14 2021-10-14 Ethris Gmbh Lipid-based formulations containing salts for the delivery of rna

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
EP1083951A4 (en) 1998-06-12 2004-07-07 Aradigm Corp METHOD FOR DISCHARGING POLYNUCLEOTIDS IN THE FORM OF AN AEROSOL IN THE RESPIRATION WAY
ATE338540T1 (de) 1999-04-02 2006-09-15 Res Dev Foundation Polyethyleneimine: dns-formulierungen für die aerosol-verabreichung
IL150027A0 (en) 1999-12-04 2002-12-01 Res Dev Foundation Carbon dioxide enhancement of inhalation therapy
WO2002000870A2 (en) 2000-06-26 2002-01-03 Christian Plank Method for transfecting cells using a magnetic field
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
MXPA05013983A (es) 2003-06-30 2006-03-02 Canji Inc Encapsulacion polimerica de adenovirus.
JP5398982B2 (ja) 2004-05-24 2014-01-29 ミダテック リミテッド Ｒｎａリガンドを含むナノ粒子
CN101090714A (zh) * 2004-07-26 2007-12-19 康泽里克斯公司 通过吸入伊洛前列素和微粒制剂治疗肺动脉高血压症
DK1871901T3 (da) * 2005-04-11 2011-10-17 Bayer Bioscience Nv Elitebegivenhed A5547-127 samt fremgangsmåder og sæt til identifikation af en sådan begivenhed i biologiske prøver
GB0508110D0 (en) 2005-04-22 2005-06-01 Univ Keele Gene delivery
DK2578685T3 (da) 2005-08-23 2019-06-03 Univ Pennsylvania Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf
DE102005041329A1 (de) 2005-08-29 2007-03-01 Kehrle, Rainer, Dipl.-Ing. Verfahren und Vorrichtung zur Herstellung eines wellpappeartigen Verbundmaterials
DE102005042768A1 (de) 2005-09-08 2007-03-15 Ludwig-Maximilian-Universität Magnetfeld-gesteuerter Wirkstofftransfer für die Aerosoltherapie
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
CN102164487A (zh) * 2008-09-25 2011-08-24 阿拉迪姆公司 曲前列素的深肺部递送
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US9289388B2 (en) * 2008-12-10 2016-03-22 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
JP5697123B2 (ja) 2009-07-27 2015-04-08 国立大学法人 千葉大学 酸性化ポリエチレンイミンを用いる細胞への核酸導入方法
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
US20110229528A1 (en) 2010-03-12 2011-09-22 Intezyne Technologies, Incorporated Pegylated polyplexes for polynucleotide delivery
ES2826203T3 (es) 2012-06-08 2021-05-17 Ethris Gmbh Suministro pulmonar de ARN mensajero
PL2968586T3 (pl) 2013-03-14 2019-01-31 Translate Bio, Inc. Kompozycje mrna cftr i związne z nimi sposoby i zastosowania

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871230B2 (en) 2009-12-21 2014-10-28 Ethris Gmbh Conjugate with target-finding ligand and use thereof
US9555122B2 (en) 2009-12-21 2017-01-31 Ethris Gmbh Conjugate with target-finding ligand and use thereof
US10080804B2 (en) 2009-12-21 2018-09-25 Ethris Gmbh Conjugate with target-finding ligand and use thereof
US10583195B2 (en) 2009-12-21 2020-03-10 Ethris Gmbh Conjugate with target-finding ligand and use thereof

Also Published As

Publication number Publication date
ES2687442T3 (es) 2018-10-25
US20140341995A1 (en) 2014-11-20
BR112012015147A2 (pt) 2016-07-12
AU2010335528B2 (en) 2014-12-04
WO2011076391A1 (de) 2011-06-30
EP2515945A1 (de) 2012-10-31
CN102770161B (zh) 2015-09-02
EP3456356A1 (de) 2019-03-20
US10583195B2 (en) 2020-03-10
US8871230B2 (en) 2014-10-28
US20190091342A1 (en) 2019-03-28
CN102770161A (zh) 2012-11-07
DK2515945T3 (en) 2018-10-01
US10080804B2 (en) 2018-09-25
ZA201204480B (en) 2013-09-25
US20170252455A1 (en) 2017-09-07
EP2515945B1 (de) 2018-07-04
JP5748768B2 (ja) 2015-07-15
EP2338520A1 (de) 2011-06-29
CA2784705A1 (en) 2011-06-30
EA023893B1 (ru) 2016-07-29
KR20120103725A (ko) 2012-09-19
CA2784705C (en) 2019-03-05
JP2013515023A (ja) 2013-05-02
US9555122B2 (en) 2017-01-31
AU2010335528A1 (en) 2012-07-12
US20120328520A1 (en) 2012-12-27
KR101769638B1 (ko) 2017-08-18
BR112012015147B1 (pt) 2022-05-10

Similar Documents

Publication Publication Date Title
EA201200919A1 (ru) Конъюгат с обнаруживающим мишень лигандом и его применение
LTPA2017019I1 (lt) Žmogaus antikūnai, pasižymintys dideliu giminingumu PCSK9
BRPI0908918A2 (pt) corpo revestido de material de elevada resistência
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
MX2009002903A (es) Combinacion de un ligando del receptor nmda y un compuesto con afinidad por el receptor 5-ht6.
CL2013000250A1 (es) Compuestos conjugados de dimeros de pirrolo[1,4]benzodiazepina; procedimiento de preparacion; y su uso como agente anticanceroso.
EA201491009A1 (ru) Гель лизата тромбоцитов
CL2012000768A1 (es) Compuestos derivados de acido l-glutamico y l-glutamina marcados con [18f]; procedimiento de preparacion; y su uso para el diagnostico de enfermedades tumorales.
UY32277A (es) Derivados de n-{[1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0-il}metil}-2heteroarilamina y uso de los mismos
CL2012002880A1 (es) Compuestos derivados de pirrolobenzodiazepinas conjugados, entre otros con anticuerpos; procedimiento de preparación de un conjugado; composicion farmaceutica: procedimiento de tratamiento de cancer; y su uso para proporcionar el compuesto a una localizacion diana que es una poblacion celular proliferativa; articulo de fabricacion
HK1132175A1 (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
EA201300084A1 (ru) Способ стерилизации по меньшей мере одного объекта, устройство стерилизации и его применение
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BR112013013369A2 (pt) ligante sigma, uso do mesmo e combinação de pelo menos um ligante sigma
EA201290777A1 (ru) Новая радиорезистентная водоросль рода coccomyxa
EA200870148A1 (ru) Производные сулиндака, их применение и получение
BR112013002441A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer
BR112013016071A2 (pt) "métodos, dispositivo e kit de diagnóstico de diabete e uso de glioxilato ou um agente de detecção para glioxilato"
CO6670086A1 (es) Sistema con un artículo absorbente sanitario de adhesión rápida
BRPI0924986A2 (pt) "combinações de substâncias ativas com propriedades inseticidas e acaricidas".
BRPI0911573A2 (pt) preservativo com agente ativo localizado.
EA201270315A1 (ru) Новые формы полициклического соединения
BR112012002311A2 (pt) composto, composição farmacêutica, e, uso do composto.
RU2010146152A (ru) Лекарственное средство с кардиопротективной активностью
MY161655A (en) Unit dosage of apadenoson

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM